The future of drug monitoring in Europe until 2030: A report summarising the findings and lessons learnt from the EMCDDA’s ‘futures study’

Introduction

Patterns of drug use and developments in the drug market in Europe are becoming more complex and dynamic, with major implications for drug monitoring and research. This observation prompted the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) to conduct a futures exercise 2030 to inform the agency’s strategic reflection on how to improve its activities in the context of both ongoing rapid changes in the information environment and the new information needs likely to emerge over the next decade. A summary of this work is provided here.

Table of contents

  • Part 1: Overview: The EMCDDA ‘futures exercise 2030'
    • Background
    • Summary of the main lessons learnt from the exercise
    • Conclusions
  • Part 2: The future of drug monitoring in Europe until 2030
    • Introduction to foresight 
    • The EMCDDA ‘futures exercise 2030’: process and methods
    • Major drivers of change 
    • Future information needs and implications for the drug monitoring system 
    • Lessons learnt from building the EMCDDA foresight toolbox
    • Conclusions
    • References
    • Further resources
Top